Pharmacology Research Today is a free monthly online journal that collates and summarizes the latest research about Pharmacology, including details on pharmacogenomics, drug development, new medications.

Volume 5 (2009), Issue 3 (March)

1. PhAST: pharmacophore alignment search tool.
   J Comput Chem, 30(5): 761-71. [Abstract] [Full-text]
2. Update on the therapy for myelodysplastic syndrome.
   Am J Hematol, 84(3): 177-86. [Abstract] [Full-text]
3. Pharmacogenomics and analogues of the antitumour agent N6-isopentenyladenosine.
   Int J Cancer, 124(9): 2179-85. [Abstract] [Full-text]
4. Persistent toxic substances in remote lake and coastal sediments from Svalbard, Norwegian Arctic: levels, sources and fluxes.
   Environ Pollut, 157(4): 1342-51. [Abstract] [Full-text]
5. Stability of titania nanoparticles in soil suspensions and transport in saturated homogeneous soil columns.
   Environ Pollut, 157(4): 1101-9. [Abstract] [Full-text]
6. Chemical stability of metallic nanoparticles: a parameter controlling their potential cellular toxicity in vitro.
   Environ Pollut, 157(4): 1127-33. [Abstract] [Full-text]
7. Pharmacokinetics and biodistribution of N-isopropylacrylamide copolymers for the design of pH-sensitive liposomes.
   Biomaterials, 30(13): 2598-605. [Abstract] [Full-text]
8. Discovery of novel triple helical DNA intercalators by an integrated virtual and actual screening platform.
   Nucleic Acids Res, 37(4): 1280-7. [Abstract] [Full-text]
9. Determination of relative assay response factors for toxic chlorinated and brominated dioxins/furans using an enzyme immunoassay (EIA) and a chemically-activated luciferase gene expression cell bioassay (CALUX).
   Environ Int, 35(3): 588-93. [Abstract] [Full-text]
10. Toxicogenomics and clinical toxicology: an example of the connection between basic and applied sciences.
    Toxicol Lett, 186(1): 2-8. [Abstract] [Full-text]
11. Pharmacogenomic approaches in clinical studies to identify biomarkers of safety and efficacy.
    Toxicol Lett, 186(1): 18-21. [Abstract] [Full-text]
12. The use of gene array technology and proteomics in the search of new targets of diseases for therapeutics.
    Toxicol Lett, 186(1): 45-51. [Abstract] [Full-text]
13. Chemical databases for environmental health and clinical research.
    Toxicol Lett, 186(1): 62-5. [Abstract] [Full-text]
14. Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development.
    Toxicol Lett, 186(1): 22-31. [Abstract] [Full-text]
15. Integrating genomics across drug discovery and development.
    Toxicol Lett, 186(1): 9-12. [Abstract] [Full-text]
16. Application of toxicogenomics to study mechanisms of genotoxicity and carcinogenicity.
    Toxicol Lett, 186(1): 36-44. [Abstract] [Full-text]
17. An FDA perspective on the nonclinical use of the X-Omics technologies and the safety of new drugs.
    Toxicol Lett, 186(1): 32-5. [Abstract] [Full-text]
18. Similar compounds searching system by using the gene expression microarray database.
    Toxicol Lett, 186(1): 52-7. [Abstract] [Full-text]
19. Ultrafast shape recognition: evaluating a new ligand-based virtual screening technology.
    J Mol Graph Model, 27(7): 836-45. [Abstract] [Full-text]
20. Design and QSAR study of analogs of gamma-tocotrienol with enhanced antiproliferative activity against human breast cancer cells.
    J Mol Graph Model, 27(7): 777-83. [Abstract] [Full-text]
21. The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease.
    Cardiovasc Drugs Ther, 23(2): 171-81. [Abstract] [Full-text]
22. Sulfotransferase gene copy number variation: pharmacogenetics and function.
    Cytogenet Genome Res, 123(1): 205-10. [Abstract] [Full-text]
23. CNVs of human genes and their implication in pharmacogenetics.
    Cytogenet Genome Res, 123(1): 195-204. [Abstract] [Full-text]
24. CNVs and genetic medicine (excitement and consequences of a rediscovery).
    Cytogenet Genome Res, 123(1): 7-16. [Abstract] [Full-text]
25. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.
    Pharmacogenet Genomics, 19(4): 300-9. [Abstract] [Full-text]
26. Guinea pig hippocampal 5-HTIE receptors: a tool for selective drug development.
    J Neurochem, 109(1): 268-74. [Abstract] [Full-text]
27. The Dutch vision of clinical pharmacology.
    Clin Pharmacol Ther, 85(4): 366-8. [Abstract] [Full-text]
28. Stimulation of cholecystokinin-A receptors with Gl181771X: a failed clinical trial that did not test the pharmacogenetic hypothesis for reduction of food intake.
    Clin Pharmacol Ther, 85(4): 362-5. [Abstract] [Full-text]
29. Novel adenosine-derived inhibitors of 70 kDa heat shock protein, discovered through structure-based design.
    J Med Chem, 52(6): 1510-3. [Abstract] [Full-text]
30. Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.
    J Med Chem, 52(6): 1522-4. [Abstract] [Full-text]
31. Aza-analogue dibenzepinone scaffolds as p38 mitogen-activated protein kinase inhibitors: design, synthesis, and biological data of inhibitors with improved physicochemical properties.
    J Med Chem, 52(6): 1778-82. [Abstract] [Full-text]
32. Octahydrophenanthrene-2,7-diol analogues as dissociated glucocorticoid receptor agonists: discovery and lead exploration.
    J Med Chem, 52(6): 1731-43. [Abstract] [Full-text]
33. Design, synthesis, and structure-activity analysis of isoform-selective retinoic acid receptor beta ligands.
    J Med Chem, 52(6): 1540-5. [Abstract] [Full-text]
34. A new statistical screening approach for finding pharmacokinetics-related genes in genome-wide studies.
    Pharmacogenomics J, 9(2): 137-46. [Abstract] [Full-text]
35. Drug development: assessment of pharmacogenetic studies by Spanish research ethics committees.
    Pharmacogenomics J, 9(2): 86-9. [Abstract] [Full-text]
36. Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening.
    Proc Natl Acad Sci U S A, 106(12): 4929-34. [Abstract] [Full-text]
37. Synthesis, pharmacological evaluation and docking studies of new sulindac analogues.
    Eur J Med Chem, 44(5): 1959-71. [Abstract] [Full-text]
38. QSAR model for predicting radical scavenging activity of di(hetero)arylamines derivatives of benzo[b]thiophenes.
    Eur J Med Chem, 44(5): 1952-8. [Abstract] [Full-text]
39. The structure-bioavailability approach in antifungal agents.
    Eur J Med Chem, 44(5): 1978-81. [Abstract] [Full-text]
40. Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) Study.
    Pharmacoepidemiol Drug Saf, 18(4): 310-9. [Abstract] [Full-text]
41. Human embryonic stem cell technologies and drug discovery.
    J Cell Physiol, 219(3): 513-9. [Abstract] [Full-text]

© 2005-2013 Pharmacology Research Today. All Rights Reserved.